Vaginal nanofiber formulations containing tenofovir disoproxyl fumarate and emtricitabine.

Layered vaginal nanofiber formulations with TDF and FTC, utilizing electrospinning technology, address the limitations of current HIV prophylaxis methods by ensuring prolonged, controlled drug release and adherence, thereby enhancing local drug concentrations and reducing systemic side effects.

TR202519189A3Active Publication Date: 2026-10-21GAZI UNIVERISTESI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TR202519189
Authority / Receiving Office
TR · TR
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-12-04
Publication Date
2026-10-21
Estimated Expiration
2045-12-04

AI Technical Summary

Technical Problem

Current HIV prophylaxis methods, such as systemic oral dosage forms and vaginal gels, rings, and ovules, suffer from systemic side effects, poor patient compliance, inadequate mucosal retention, and short-lived drug release, failing to achieve effective local drug concentrations in the vaginal mucosa.

Method used

Development of layered vaginal nanofiber formulations containing Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) using electrospinning technology, with a mucoadhesive outer layer for adherence and a controlled-release middle layer, ensuring prolonged drug delivery directly to the vaginal mucosa.

Benefits of technology

The nanofiber formulations provide long-lasting, controlled release of antiretroviral drugs, reducing systemic side effects and enhancing local drug concentrations, thus improving patient compliance and efficacy in preventing vaginal HIV transmission.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This relates to electrospinning-produced, layered vaginal nanofiber formulations for local prophylaxis against vaginal transmission of HIV / AIDS. The formulation contains Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC). Thanks to its mucoadhesive properties, it adheres firmly to the vaginal mucosa, providing long-lasting local drug release. Its layered structure and controlled release profile increase its effectiveness and reduce systemic side effects.
Need to check novelty before this filing date? Find Prior Art

Description

1 35 40 45 TARIFF TENOFOVIR DISOPROXIL FUMARATE AND EMTRICITABINE VAGINAL NANOFIBER FORMULATIONS Technical Area Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) administered via electroconvulsive therapy. This relates to manufactured, layered vaginal nanofiber formulations. State of the technology The combination of TDF / FTC is commonly used in current HIV prophylaxis and treatment approaches. Systemic oral dosage forms are used. These systems undergo first-pass metabolism. Risks of complications, gastrointestinal side effects, systemic toxicity, and poor patient compliance. It has disadvantages such as being... Alternatively, vaginal gels, rings and... have been developed. Ovules, on the other hand, generally exhibit short-lived effect, irregular release, and inadequate mucosal retention. It has limitations. Currently, Tenofovir Disoproxil is used for prophylaxis and treatment against HIV / AIDS. Antiretroviral drugs such as fumarate (TDF) and emtricitabine (FTC) are commonly available in oral tablet form. It is used as such. However, this systemic application has undesirable systemic side effects, high patient compliance to treatment and adequate drug concentration in the vaginal mucosa are required. It has certain limitations, such as inaccessibility. Drug delivery systems such as gels, rings, ovules, and films for vaginal application are being developed, These deliver targeted local release, reducing systemic side effects and benefiting the patient. It offers an advantage in terms of increasing compatibility. In recent years, nanotechnology-based carriers have been used. It is particularly a focus of research. For the prevention of HIV infection and contraception by WOODROW and colleagues. Consisting of polymer fibers produced by electrospinning, with at least the same or different fibers within them. A drug delivery system containing two drug active ingredients has been identified (US2014128345 A1, US9393216 B2). The active antiviral drug to be combined includes Emtricitabine (FTC). It is not included. The active antiviral drug ingredients are miraviroc (MVC), cyanovirin-N (CV- N), tenofovir (TFV), dapivirine (DPV), etravirine (ETR), azidothymidine (AZT), acyclovir (ACV), raltegravir (RAL) is indicated. Controlled-release, mucoadhesive, and combined pigments produced by electrospinning. Vaginal nanofiber systems containing antiretroviral drugs have not yet entered clinical use. This Studies in this field are generally limited to the in vitro level, and the standardization of products is lacking. and clinical trials are needed to determine its clinical validity. (Nunes, R., Bogas, S., Faria, M.J., Gonc;:alves, H., Lucio, M., Viseu, T., ... & das Neves, J. (2021). Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis. Journal of Controlled Release, 334, 453-462.) The developed invention offers an alternative to existing prophylactic methods for preventing vaginal transmission of HIV / AIDS. It aims to offer solutions to the inadequacies of current treatment approaches for HIV. Systemic prophylaxis methods used in protection against disease; difficulty of application, patient compliance low levels of the drug, systemic side effects, and failure to achieve adequate local drug concentrations. It has significant limitations. Furthermore, current vaginal applications are generally short-acting. It provides, and also has insufficient mucoadhesive properties to effectively breach biological barriers. They can't get through. 2 Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) were developed within the scope of this invention. Vaginal nanofiber formulations containing; with their mucoadhesive properties, they remain on the vaginal mucosa for a long time. It is able to adhere to and release the active substance at the desired time and dose by performing controlled drug release. It can provide this and reduces systemic side effects with a local effect. Also, electrocautery 5 Thanks to the multilayered nanofiber structures obtained by this method, both physical and biological Obstacles are being overcome. Brief Description of the Invention This invention offers a local, effective, and patient-friendly solution for preventing vaginal transmission of HIV. It is concerned with developing a drug delivery system that improves compliance. The current systemic 10 issues with bioavailability of treatments, systemic side effects, and irregular medication use, etc. As a solution to the disadvantages; a combined solution with controlled release and mucoadhesive properties. A vaginal nanofiber formulation containing antiretroviral drugs (TDF and FTC) has been developed. The stratified system addresses local bioavailability problems where existing methods are insufficient. It aims to solve systemic side effects and patient compliance problems; very 15 Layered (stratified), mucoadhesive nanofiber formulations for electrospinning. This will be achieved through the method. Nanofibers obtained thanks to electrospinning technology, precisely controlling the release profiles of drugs and targeting them in the vaginal mucosa, It provides effective local protection by delivering long-lasting drug concentration. Thanks to this system, antiretroviral drugs are delivered directly to the target area via local application within 20 days. delivery, increased mucosal permeability, and thus enhanced efficacy, thereby minimizing systemic side effects. The effects are being reduced. The layered nanofiber formulation developed in this invention is formed into layers using the electrospinning method. manufactured in such a way that each layer has different functions or drug loads It consists of a designed structure. In the layered system; the first layer is mucoadhesive 25 It consists of polymers (e.g., PVA, PVP) and adheres tightly to the vaginal mucosa, thus strengthening the formulation. It ensures that the product remains in the application area for a long time. The second layer contains a hydrophobic or slow-release polymer that provides controlled release. (e.g., zein or PLGA) and regulate the drug release rate. Interlayer transition is based on the principle of controlled diffusion, which both extends the emission profile and... 30 It also helps prevent side effects. Thanks to this structure, different types of standards like TDF and FTC can be used. Drugs with different solubility profiles are positioned within the layer, each targeting its intended purpose. Release was ensured in the appropriate duration and rate. The multilayer structure in question allows for the electromagnetic parameters (current, solution content, This was achieved by controlled adjustment of viscosity, number of needles, and collector type. 35 Advantages of the Invention This invention provides an effective, reliable, and patient-compliant solution for preventing the vaginal transmission of HIV. It offers a locally produced drug delivery system that enhances and is technologically feasible, thus providing global public health services. It offers an innovative and practical solution to a problem that threatens health. 40 Combined antiretroviral drug (TDF+) developed for use in HIV / AIDS prophylaxis. With a controlled-release, mucoadhesive, layered vaginal nanofiber formulation containing FTC. It represents a significant innovation, both technically and commercially. Thanks to its mucoadhesive properties, it adheres firmly to the vaginal mucosa, providing long-lasting local drug release. Its layered structure and controlled release profile increase efficacy while reducing systemic side effects. 45 3 Furthermore, its applicability via applicator and user-friendly design are significant advantages over existing systems. It has advantages. This invention produces layered, TDF using an electrospinning method. A combined antiretroviral drug (FRC) mucoadhesive vaginal nanofiber formulation is available. Compared to other solutions, it offers the following unique and advantageous aspects: 5 1. Multilayer nanofiber capable of carrying dual drugs: TDF and FTC, with separate release profiles. This structure allows for the control of release kinetics through polymer selection and fiber morphology. It allows for modulation. Unique aspects of layered nanofiber structures: Interlayer transition is based on the principle of controlled diffusion, which both extends the emission profile and... 10 It also helps prevent side effects. Thanks to this structure, different types of standards like TDF and FTC can be used. Drugs with different solubility profiles are positioned within the layer, each targeting its intended purpose. The release can be achieved in a controlled duration and rate. It offers a local and prolonged effect with no first-pass effect. 2. Electrospinning-produced porous fiber matrix with high surface area: Thanks to this structure This ensures controlled, prolonged, and targeted release of the drug. This is achieved with conventional film or gel 15 It offers a more stable pharmacokinetic profile compared to other formulations. 3. Mucoadhesive polymer-based formulation (PVA, PVP, Zein, PLGA, etc.): Applied to the vaginal mucosa. By providing strong adhesion, the formulation remains in the local area for a long time, thus ensuring the drug's... It maximizes mucosal absorption. 4. Reduction of systemic toxicity by local application: The invention relates to the reduction of systemic toxicity of drugs that enter the systemic circulation. By reducing the dosage, it minimizes side effects and places a minimum systemic burden on the patient. 5. Optimizing production parameters for electrospinning: This process involves the nanofibers. This ensures homogeneous, bead-free output with the targeted diameter; this, in turn, affects the release profile. It has a direct effect. 6. Formulation that can be applied with an applicator: The nanofiber structure is cut appropriately and 25 It is possible to implement it through a standard applicator for the user. This situation, Ease of use, repeatable dosage, and hygienic application are significant advantages. It provides. With these technical specifications, the invention differs from existing local drug delivery systems in the literature. Structural design, carrying capacity, release control, and mucoadhesion properties; HIV in the vagina 30 It stands out as an effective, safe, and user-friendly prophylaxis tool against transmission via this route. is doing. Unlike traditional vaginal formulations, its dry and rigid nanofiber structure prevents leakage. No problems such as leakage are observed, and therefore superior stability with a long shelf life. It provides an advantage. 35 Explanation of the Figures In vitro release studies conducted in Franz diffusion cells. Release profiles of PVA-based mucoadhesive nanofiber formulations from dialysis membranes. Figure 1. Release profiles of active ingredients from F1-TF nanofiber formulation 40 Figure 2. Release profiles of active ingredients from F2-TF nanofiber formulation. Figure 3. Release profiles of active ingredients from F4-TF nanofiber formulation. 4 Release profiles of zein-based nanofiber formulations from dialysis membranes. Figure 4. Release profiles of active ingredients from Z2-TF nanofiber formulation. Figure 5. Release profiles of active ingredients from ZK7-TF nanofiber formulation. Figure 6. Release profiles of active ingredients from ZK8-TF nanofiber formulation 5 Figure 7. Release profiles of active ingredients from ZK9-TF nanofiber formulation. Figure 8. Release profiles of active ingredients from ZK10-TF nanofiber formulation. Release profiles of PLGA-based blend nanofiber formulations from dialysis membranes. Figure 9. Release profiles of active ingredients from M1-TF nanofiber formulation 10 Figure 10. Release profiles of active ingredients from M2-TF nanofiber formulation. Release profiles of layered PLGA nanofiber formulations from dialysis membranes. Figure 11. Release of active substances from S1-TF (in vivo group D) nanofiber formulation. profiles 15 Figure 12. Release profiles of active ingredients from S2-TF nanofiber formulation. Figure 13. Release profiles of active ingredients from S3-TF nanofiber formulation. Figure 14. Release profiles of active ingredients from S4-TF nanofiber formulation. In vitro release studies using the USP basket method 20 Figure 15. In vitro release profile of TDF and FTC from the F4-TF formulation. Figure 16. In vitro release profile of TDF and FTC from M2-TF formulation. Figure 17. In vitro release profile of TDF and FTC from S1-TF formulation. Ex vivo Studies on Nanofiber Formulations 25 Ex vivo permeability studies Figure 18. Permeability profile of F4-TF nanofiber formulation from bovine vaginal tissue. Figure 19. Permeability profile of M2-TF nanofiber formulation from bovine vaginal tissue. Figure 20. Permeability profile of S1-TF nanofiber formulation from bovine vaginal tissue. Ex vivo involvement studies 30 Figure 21. Results of vaginal retention study with F4-TF Nanolif formulation % Figure 22. Vaginal retention study results from M2-TF Nanofiber formulation. 35 Detailed description of the invention. The subject of the invention is a layered nanofiber formulation produced by electrospinning; containing PVA. layer, release regulator with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC). a middle layer containing zein or poly(lactide-co-glycolide) (PLGA) as a polymer and containing PVA It has three layers, including the outer layer. 5 Polyvinyl alcohol (PVA) was used as the polymer for both the inner and outer layers. PVA dissolves in water. It is a soluble, biocompatible, and highly mucoadhesive polymer. For this purpose, Polyviol three types: 13 / 140 (49,000 Da), Polyviol 26 / 140 (80,000 Da) and Polyviol 40 / 140 (100,000 Da). Different types of PVA were used. As a result of the experiments, PVA could be combined with different polymers. Polyviol 13 / 140 10 with a molecular weight of 49000 will enable its development in this way. N,N- has been selected as the solvent system for the preparation of PVA solutions. Dimethylformamide (DMF): Distilled water or a 1:1 ratio of distilled water to ethanol can be used. PVA The solution should be 10% PVA concentration in a 1:1 ratio of distilled water to ethanol. It has been prepared by solving the problem. Improving the surface properties of the fibers to increase mucosal adhesion and enhance flexibility and resistance. 15 Combined with PVA in the inner and / or outer layer to balance mechanical strength. Polyvinylpyrrolidone (PVP) and polyethylene oxide (PEO) are used as additional polymers. A polymer selected from pullulan, gluten, chitosan, and beta-cyclodextrin may be used. (Invention) The use of PVP was chosen for this purpose. The combination of PVA and PVP was used to develop the vaginal medication. It ensures a tighter adherence to the mucosa. The average molecular weight of PVP K90 used is 20. It is 360,000. For mucoadhesive nanofiber formulations that can be produced by electrospinning, 10% PVA. A 5% PVP K90 mixture was used. The nanofiber formulation described in the invention has a middle layer containing zein or PLGA as a polymer. Zein is a naturally occurring, hydrophobic, and biodegradable protein derived from corn, available in controlled release. In order to slow down the release in the system and strengthen the structural integrity of the fiber 25 Zein has used nanofibers that carry combined antiretroviral drugs via electrocautery. Its use is a unique approach, especially for vaginal applications. The presence of many uncharged amino acid residues in the structure of zein makes it insoluble in aqueous environments. This happens, but only at certain ethanol concentrations, with anionic surfactants, or It dissolves in alkaline solutions. For the preparation of polymer solutions containing zein, use an 8:2 30 ratio. The mixture was prepared using a ratio of ethanol:distilled water. PLGA is a biodegradable copolymer ideal for slow and controlled drug release. It is a carrier. The PLGA layer is located in the middle layer of the nanofibers, extending the release profile. It acts as a barrier. The combined use of PLGA with PVA or zein in a layered system, It provided bidirectional control over controlled release. Preparation of PLGA-containing nanofibers 35 For this, an Acetone:DMF solvent mixture is used in a 9:1 volume ratio. Three-layered nanofiber formulation developed using the electrospinning method, containing PVA and PVP. inner layer containing Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) for release The midlayer, containing zein or PLGA as a regulatory polymer, adheres to the vaginal mucosa. It has three layers, including an outer layer containing PVA and PVP. HIV / AIDS is transmitted vaginally in 40 days. Developed nanofiber formulation to be used for local prophylaxis to prevent infection. Each unit contains 90 mg of Tenofovir Disoproxil Fumarate and 60 mg of Emtricitabine. In formulations developed with PVA polymer, additives are used to ensure controlled release. Sandwich-structured nanofiber formulations have been developed. Each layer has different properties. Thanks to the inclusion of polymers, both mucoadhesion and controlled release are achieved simultaneously. 45 These combinations have been optimized to accommodate the different solubility and diffusion profiles of the drugs. It has been adapted accordingly. 6 In conclusion, the polymers used are determined by their intended uses, combinations, and layering. It offers a unique approach in terms of the functional distributions within the structure. Fiber morphology control, increased mucoadhesion, and the use of different active ingredients. The ability to integrate emission profiles within the same system makes this polymer-based system innovative. It constitutes its aspects. 5 In the production of the product developed by the electrospinning method, after the inner PVA layer is prepared... The PLGA-containing middle layer is superimposed on the first layer. TDF and FTC are only present in the middle layer. PLGA was added to the polymer solution. Then the outermost layer was produced. It has been accomplished. Development work and examples 10 Development strategies for our vaginal nanofiber formulations for HIV pre-exposure prophylaxis. as listed below: • We started our studies with PVA, which exhibits high mucoadhesive properties and facilitates easy fiber production. It has begun. • Among the different types of PVA, the most suitable PVA we can produce by electrospinning is 15. Preliminary formulation studies have been carried out to determine the type. • After determining the PVA type, preliminary formulation studies were carried out according to the design. • Different methods to enhance the mucoadhesive properties of PVA-based nanofibers in vaginal applications. A new group of formulations has been created by adding mucoadhesive polymers. • With zein, a natural polymer that increases the duration of stay and release time in the vagina. 20 Nanofiber studies have been carried out. Mechanical properties of nanofibers prepared with Zein. Since vaginal application is infrequent, alternative methods such as PEO and PVP are used. Formulations have been prepared. • Nanofiber formulations containing PLGA have been prepared for the purpose of controlled release. Polymers such as PVP and PEO are used to enhance the mucoadhesive properties of the formulations. Combinations have been examined. • Layered formulations to slow down release in PLGA-based formulations These formulations have been prepared. To enhance their mucoadhesive properties, they have been layered with PVA. Nanofiber formulations have been investigated. For determining the optimum formulation, the 30 nanofiber formulations were used as the dependent variable. Mechanical and mucoadhesive properties were selected, and the targeted mechanical properties were achieved. This is shown in Table 1. Table 1. Characteristics of targeted vaginal formulations. Tensile strength >1 MPa Elongation at break >50% In nanofiber formulations, the independent variables are: polymer concentration and collector concentration. The rotational speed and solvent system were selected. Polymer 35, in which nanofiber production can be carried out. 23 concentrations, different solvent systems and collector rotation speeds were taken into consideration A statistical experimental design model was created using factorial experimental design (Table). 2). 7 Table 2. Factorial Design used in nanofiber formulations. parameters Independent variable In the formulations factor levels Answers Polymer Concentration 7.5%-15% Tensile Strength (MPa) Elongation at Break (%) Collector Rotation Speed: 100 rpm-1000 rpm Solvent System Distilled Water: Ethanol- Distilled Water: DMF Factorial design with 2 factors (upper and lower values), 3 variables (polymer concentration-solvent 5 8 formulations with system-collector rotation speed) using Design Expert® 13 software created (Table 3). Table 3. Determined DoE designs for the development of nanofiber formulations. parameters Design Formulations Polymer Concentration (X1) Solvent System (X2) Collector Rotation Speed (X3) RUN 1 7.5% Ethanol / Distilled Water 100 rpm RUN 2 7.5% DMF / Distilled Water 100 rpm RUN 3 7.5% Ethanol / Distilled Water 1000 rpm RUN 4 15% DMF / Distilled Water 1000 rpm RUN 5 15% Ethanol / Distilled Water 1000 rpm RUN 6 15% DMF / Distilled Water 100 rpm RUN 7 7.5% DMF / Distilled Water 1000 rpm RUN 8 15% Ethanol / Distilled Water 100 rpm Development Studies of PVA-Based Mucoadhesive Nanofibers PVA was chosen as the base polymer and nanofiber formulations for vaginal application. By using different polymers to improve their mechanical and mucoadhesive properties Formulation studies have continued. The studies focused on mucoadhesive and biodegradable materials. Specifically, PVP, PEO, pullulan, gluten, and chitosan are 15 commonly used in vaginal applications. They are polymers. A common solvent system is selected for the polymer used to create nanofibers. Formulations have been successfully produced. Formulations are in distilled water:ethanol (1:1) It was prepared by dissolving it and mixing it with polymer solutions at different concentrations. In the F5 formulation... DMF was used instead of ethanol (Table 4). In the preparation of nanofibers containing active ingredients, 90 20 is used in a 10 mL solution. It contains mg TDF and 60 mg FTC. Mechanical properties of PVA formulations prepared with different polymers have been tested. 8 By keeping the volume of solution used for the PVA layer constant, the amount of PVA solution used... The voltage values ​​have changed. In the production of PVA nanofibers, 18-19 kV voltage values ​​and 1.2-1.5 mL / h flow rates are used. Production was carried out in the 150 mm-160 mm range using the given values. In the fibers Mechanical properties (elongation at break and stress at break), contact angles, and Formulations showing the best properties as a result of determining mucoadhesive characteristics are 5 By identifying the active ingredients, final formulations loaded with active substances were developed. Table 4. Composition and solvent system of mucoadhesive nanofiber formulations. Code PVA (%) Pullulan (%) PVP (K90) (%) PEO (N80) (%) Gluten (%) Chitosan (LMW) (%) β-CD (5%) F1 10 - - - - - - F2 10 5 - - - - - F3 10 - 5 - - - - F4 10 - - 5 - - - F5 10 - - - 5 - - F6 10 - - - - 0.5 - F7 10 - - - - - 5 PVA-based mucoadhesive nanofiber formulations containing TDF and FTC. TDF is the optimum formulation developed with PVA-based mucoadhesive nanofiber formulations. Nanofiber formulations were successfully produced by electrospinning with the addition of FTC. 10 The 5 formulations produced have a voltage between 16.5-21 kV, a flow rate between 0.5-1 mL / h, and a diameter of 110-160 mm. They are manufactured with a distance between them and a rotation speed of 100 rpm (F1-TF, F2-TF, F3-TF, F4-TF, F5-TF) Characterization of formulations prepared by combining PVA with different polymers. Studies were conducted on the mechanical properties of the fibers (elongation at break and The best properties were determined as a result of determining the breaking strength, contact angles and mucoadhesive properties of 15. Formulations displaying TDF and FTC are loaded with active ingredient-loaded formulations. These formulations were developed as a result of nanofiber characterization studies, which revealed the best mechanical properties. and formulations that exhibit mucoadhesive properties (Table 5). Table 5. Composition of PVA-based mucoadhesive nanofiber formulations containing TDF and FTC. Solvan system 20 CODE TDF FTC PVA (%) PULLED (%) PVP (%) PEO (%) F1-TF 90 60 10 - - - F2-TF 90 60 10 5 - - F3-TF 90 60 10 - 5 - F4-TF 90 60 10 - - 5 9 Preparation of nanofiber formulations containing zein. The optimum was determined as a result of characterization studies performed on zein-containing nanofibers. Nanofiber formulations were developed by loading TDF and FTC onto the formulations (Table 6). In the polymer solvent system, TDF and FTC are first dissolved and then added to the polymer mixture to be used. It was added. It was stirred in a magnetic stirrer until a homogeneous mixture was obtained. 5 To remove air bubbles, bathe in an ultrasonic bath for 1 minute before the electrophysiology process. It was expected. Table 6. Composition of zein-based nanofiber formulations containing TDF and FTC. Code TDF FTC Zein PVP K90 Z2-TF 90 60 %30 N3-TF 90 60 %10 K3-TF 90 60 %10 %5 K7-TF 90 60 2.5% 10% K8-TF 90 60 5% 10% K9-TF 90 60 %10 %10 K10-TF 90 60 30% 15% The presence of many uncharged amino acid residues in the structure of zein makes it insoluble in aqueous environments. This happens, but only at certain ethanol concentrations, with anionic surfactants, or It dissolves in alkaline solutions. For the preparation of polymer solutions containing zein, the ratio is 8:2. Ethanol:distilled water was used in a ratio of ethanol to water. Zein has low mechanical and mucoadhesive properties. Because of this, different polymers are used in formulations to enhance these properties. Combinations have been examined. In formulations prepared with zein alone, zein is directly present in 15 It was dissolved in the solvent system. In its mixtures prepared with other polymers, PVP K90, PEO WSR205 or PEO N80 was added to the zein mixture. Mix until homogeneous. It was stirred in a magnetic stirrer at 500 rpm. Table 7. Composition of nanofiber formulations developed with Zein 20 Code Zein PEO WSR 205 PEO N80 PVP K90 Formulations containing zein Z1 20% Z2 30% Formulations containing Zein-PEO WSR 205 ZW0 %1 ZW1 2.5% 1% ZW2 5% 1% ZW3 10% 1% ZW4 20% 1% Formulations containing Zein-PEO N80 ZN0 5% ZN1 2.5% 5% ZN2 5% 5% ZN3 10% 5% ZN4 20% 5% ZN5 30% 5% Formulations containing Zein-PVP ZK0 5% ZK1 2.5% 5% ZK2 5% 5% ZK3 10% 5% ZK4 20% 5% ZK5 30% 5% ZK6 10% ZK7 2.5% 10% ZK8 5% 10% ZK9 10% 10% ZK10 30% 15% Zein-based nanofiber formulations containing TDF and FTC. Characterization studies performed on zein-containing nanofibers revealed the optimum Nanofiber formulations were developed by loading TDF and FTC onto the formulations. Polymer First, TDF and FTC were dissolved in the solvent system and then added to the polymer mixture to be used. 5 The mixture was stirred in a magnetic stirrer until a homogeneous mixture was obtained. Electromagnetic field. The sample was left in an ultrasonic bath for 1 minute before the procedure to remove air bubbles. Table 8. Composition of zein-based nanofiber formulations containing TDF and FTC. Code TDF FTC Zein PEO N80 PVP K90 Z2-TF 90 60 %30 N3-TF 90 60 %10 %5 K3-TF 90 60 %10 %5 K7-TF 90 60 2.5% 10% K8-TF 90 60 5% 10% K9-TF 90 60 %10 %10 K10-TF 90 60 30% 15% 11 PLGA-based blended nanofiber formulations PLGA polymer was tested in formulations to achieve longer-lasting release. A 1:1 ratio of DCM:DMF solvent system was used for the preparation of PLGA nanofibers. Next, the other polymer to be used in the formulation is weighed in the required amount and added to this mixture. It was added. It was stirred in a magnetic stirrer until a homogeneous mixture was obtained. 5 To remove air bubbles, bathe in an ultrasonic bath for 1 minute before the electrophysiology process. It was expected. Table 9. Content and formulation codes of PLGA-based formulations loaded with TDF and FTC. Code TDF FTC PLGA PEO N80 PVP K90 M1-TF 90 60 %10 M2-TF* 90 60 %10 %5 M3-TF 90 60 10% 5% Development of layered nanofiber formulations In formulations developed with PVA polymer, additives are used to ensure controlled release. Sandwich-structured nanofiber formulations have been developed. For the preparation of PLGA nanofibers... A 9:1 ratio Acetone:DMF solvent system was used. Layered fiber made with PLGA. In formulations, layered production with PLGA in the middle and PVA on both sides. 15 This was carried out. Different formulations were prepared by varying the thickness of the PVA layer. To improve the mucoadhesive properties of the formulations, a constant concentration of 10% PVA is used. It was prepared by dissolving PVA in distilled water:ethanol in a 1:1 ratio. The first PVA After the first layer was prepared, the PLGA layer was fabricated on top of the first layer. TDF and FTC It was added only to the PLGA polymer solution in the middle layer. Then, the outermost layer 20 Production was carried out (Table 10). The 5 formulations produced were suitable for voltages between 16.5-21 kV and 0.5- With a flow rate between 1 mL / h, a distance between 110-160 mm, and a collector rotation speed of 100 rpm. It has been produced (F1-TF, F2-TF, F3-TF, F4-TF, F5-TF) Table 10. Composition and formulation codes of TDF and FTC loaded layered nanofiber formulations 25 CODE TDF FTC PVA (10%) PLGA (10%) PVA (10%) For the top layer solution used quantity (mL) For the middle class solution used quantity (mL) For the substrate solution used quantity (mL) S1-TF 90 60 1 10 1 S2-TF 90 60 2.5 10 2.5 S3-TF 90 60 5 10 5 S4-TF 90 60 7.5 10 7.5 12 Studies Related to Formulation Characterization Studies of Active Substances and Polymers Differential scanning calorimetry (DSC) analyses In pre-formulation studies, DSC analyses revealed differences between TDF, FTC, and the polymers used. It was used to assess compatibility. In our studies, TDF, FTC and 5 were used. Analysis of 1:1 mixtures of polymers using differential scanning calorimetry. This was carried out by examining the thermograms of the individual substances and their mixtures to determine their interactions. It has been evaluated. FTIR analysis In pre-formulation studies, FTIR is the 10-degree difference between the active and excipient substances. It has been used to investigate compatibility. Spectra of single substances and mixtures of substances. The interactions were evaluated by examining the data. Solution Characterization of Polymer Mixtures to be Used in Electrospinning Processes Polymer solutions, both containing and not containing active ingredients, to be used in the electrospinning process. They were characterized by viscosity, conductivity, and surface tension measurements. The 15 obtained... Based on the results, the suitability of the systems for the electromagnetic process was evaluated. Conductivity measurements of active substance / polymer mixtures. In the electromagnetic method, the transfer of electric charge from the electrode to the polymer droplet is performed. This requires, therefore, the minimum electrical charge in the solution for the electrospinning method. Conductivity is required. In the electrospinning process, 20 nanofibers with low conductivity are used for nanofiber formation. In polymer solutions, a transition from a droplet structure to a Taylor cone shape cannot be achieved, and nanofibers cannot be obtained. It cannot be done. Non-conductive solutions cannot undergo electrospinning. Conductivity, the electric field present on the surface of the polymer solution to be used in the electrospinning process It indicates the number of charges and controls the tendency to form nanofibers. The polymer, When dissolving in a solvent, the conductivity of the solution depends on the ionic species in the polymer. electrical conductivity changes with increasing polymer concentration in the solution. may decrease or the solution may have polyelectrolyte type ionic properties if the polymer itself has such properties. Its conductivity will increase. In electrospinning, the jets formed carry more charge, leading to a decrease in the diameter of the nanofibers. This is the reason. In general, electrospinning nanofibers with small fiber diameters have a maximum diameter of 30. It can be obtained from a solution that has conductivity. Therefore, the polymer to be used... The conductivity values ​​of solutions and mixtures have been investigated. What is the electrical conductivity of a solution? how well it transmits depends on the mobility of the ions, the concentration of the solution, and the valence of the ions. and varies depending on temperature. Fiber drawing results from the very low conductivity value. If this does not happen, adding salt to the polymer solution is an alternative solution. Conductivity 35 Since its value is a parameter that determines the fiber diameter, the conductivity of the solutions is measured in µS / cm. The values ​​were measured. For the measurement, the probe of the device was immersed in the polymer solution. It was allowed to stabilize. Measurements were repeated three times for each polymer. Surface tension measurements of active ingredient / polymer mixtures. Surface tension is the force applied per unit length to increase the surface area by 1 cm². Surface 40 Voltage is a function of the composition and plays a critical role in the electromagnetic process. It is the primary force that opposes the applied voltage during the electroattraction process. Electroattraction In nanofiber formation by this method, the low surface tension of the polymer solution is due to the jetting process. The formation of beads occurs by reducing the surface tension of the polymer solution. It can reduce or prevent its formation. 45 13 In our studies, surface tension measurements were performed using the hanging drop method. In the suspended drop method, a specific tube is suspended from the needle tip of a syringe filled with a polymer mixture. The shape of the droplet, of that size, was recorded as an image by the device. The droplet's gravity The result of the balance between the force and the surface tension of the liquid is that the needle hangs from the tip without falling off. It is analyzed in its remaining state. Attension-Theta Lite 5 using the hanging drop method. The device measures the surface tension of mixtures by placing drops on the tip of a needle. Measurements were created using a 1.7% FPS measurement value at room temperature. It has been accomplished. Performing viscosity measurements of active ingredient / polymer mixtures. In the electrospinning process, the flow of the very high viscosity solution and fiber production become difficult, while very 10 Formation of continuous and uniformly structured fibers from low-viscosity polymer solutions This cannot be observed. Changes in the molecular weight and distribution of polymers affect viscosity. It strongly influences the fiber diameter. Furthermore, the viscosity of the solution is a significant factor affecting the fiber diameter. It is one of the parameters. Therefore, the viscosity values ​​of the polymer solutions we prepare are important. It has been examined. 15 The viscosity of liquids is the amount of friction encountered by the shear force applied to the fluid. It is a measure of resistance. Different methods are used for viscosity measurements. In our studies, viscosity measurements were performed using a rotating shaft / treble. Polymer Brookfield Programmable, DIII for measuring the viscosity of solutions / mixtures. A viscometer was used. For measurements, 0.5 mL of sample was placed inside the device and the room temperature was set to 20°C. This process was repeated 3 times at the specified temperature. Production of Nanofiber Formulations by Electrospinning Method The prepared polymer solutions are collected by a rotary cylinder collector in the NE300 electropulling device. Produced using [methods]. The content and production parameters of all formulations produced. They are classified and coded according to the polymer used. Solutions are added to 10 mL syringes (25 ml each). The voltage values ​​for jet formation in the electromechanical device are between 3-25 kV. It has been tested. The distance between the needle tip collector and the solvent system used in the solutions 5-20 cm to prevent evaporation and wetting of the fibers collected on the cotton cloth. Fiber production was achieved by testing at appropriate distances for each formulation. The rotational speed of the rotary cylinder was selected as 100-1000 rpm depending on the formulation. Distance 30 and after adjusting the rotation speed, different flow rates are used depending on the concentration of the formulations. Suitable fibers were obtained through experimentation. Production of PVA-containing formulations by electrospinning method. Different process parameters were applied depending on the type and concentration of PVA used. Nanofiber formulations produced with different types of PVA are used in the electrospinning method. Production parameters are given in the table. Table 11. Process parameters used in the production of PVA nanofibers. Formulation Code Voltage (kV) Flow Rate (mL / h) Distance (mm) Rotational Speed (rpm) P1 18.2 1 90 500 P2 18.5 0.9 95 500 14 P3 17.7 0.5 95 500 P4 14.5 1.5 115 500 P5 15.9 1.2 132 500 P6 14 0.5 145 500 P7 16.5 1 125 500 P8 15 0.7 148 500 P9 18 1 130 500 Production of nanofibers developed through experimental design by electrospinning method. In PVA nanofiber production, QbD is used to optimize formulation content and production process. to examine the effect of different parameters in the developed formulations and nanofibers The production of formulations developed to observe changes in formulations 5 The parameters are given in the table. Depending on the PVA concentration, solvent system, and rotation speed during production. The changes in the parameters of the electrocautery method were also observed. Other Changes occurring in the electromagnetic method while keeping the parameters the same. This has been examined. This is important for determining production parameters for subsequent studies and 10 This will make it easier to predict production parameters. Table 12. Process parameters used in the production of PVA nanofibers developed by design. Formulation Code Voltage (kV) Flow Rate (mL / h) Distance (mm) Rotational Speed (rpm) RUN 1 19.5 1.3 110 100 RUN 2 20 1 100 100 RUN 3 18.5 1 110 1000 RUN 4 19 0.8 130 1000 RUN 5 18 0.8 130 1000 RUN 6 17.5 0.7 110 100 RUN 7 19.5 0.9 105 1000 RUN 8 17.5 0.5 120 100 Production of PVA-based mucoadhesive nanofibers by electrospinning method 15 Different production methods depend on changes in polymer solutions according to polymer ratio and type. Nanofiber formulations were obtained using these parameters. Table 13. Production parameters of PVA-based mucoadhesive nanofiber formulations. Formulation Code Voltage (kV) Flow Rate (mL / hr) Distance (mm) Collector Rotation Speed ​​(rpm) F1 17.5 0.5 110 100 F2 21 0.5 120 100 F3 19 0.5 110 100 F4 16.5 0.6 160 100 F5 20 1 110 100 F6 22 0.5 105 100 F7 20 1 110 100 PVA-based mucoadhesive nanofiber formulations containing TDF and FTC. TDF is the optimum formulation developed with PVA-based mucoadhesive nanofiber formulations. Nanofiber formulations were successfully produced by electrospinning with the addition of FTC. 5 Table 14. Production parameters of mucoadhesive PVA-based nanofiber formulations containing TDF and FTC. Code Voltage (kV) Flow Rate (mL / hr) Distance (mm) Collector Rotation Speed (rpm) F1-TF 17.5 0.5 110 100 F2-TF 21 0.5 120 100 F3-TF 19 0.5 110 100 F4-TF* 16.5 0.6 160 100 F5-TF 20 1 110 100 Production of zein-containing nanofiber formulations by electrospinning method. Because nanofibers produced using zein have low mechanical properties, different polymers are preferred. 10 The aim was to improve its mechanical and mucoadhesive properties by using it. Table 15. Production parameters of zein-containing nanofiber formulations. Formulation Code Voltage (kV) Flow Rate (mL / hr) Distance (mm) Collector Rotation Speed (rpm) Z1 20.5 0.3 80 100 Z2 20.5 0.4 100 100 ZW0 6.5 0.6 200 100 ZW1 8 1 200 100 ZW2 5.5 1.5 190 100 ZW3 7 1 230 100 ZW4 7 2 225 100 16 ZN0 16 1 120 100 ZN1 16.5 1.5 105 100 ZN2 13.5 1.8 120 100 ZN3 12.5 0.5 115 100 ZN4 13 2.5 120 100 ZN5 13.5 1.5 130 100 ZK0 17.5 2 120 100 ZK1 16.5 2.5 110 100 ZK2 17 1.5 120 100 ZK3 16.5 2.4 120 100 ZK4 17 2 125 100 ZK5 16.5 0.5 165 100 ZK6 16.5 7.5 130 100 ZK7 16.5 2 120 100 ZK8 16.5 1 155 100 ZK9 16.5 2.2 155 100 ZK10 17 1.3 155 100 The products were manufactured by adding TDF and FTC to the selected optimum formulations. Effective The nanofiber production parameters change with the addition of different materials. Table 16. Production parameters of zein-based nanofiber formulations containing TDF and FTC. 5 Formulation Code Voltage (kV) Flow Rate (mL / hr) Distance (mm) Collector Rotation Speed ​​(rpm) Z2-TF 20.5 0.5 90 100 ZN3-TF 20 1.5 12 100 ZK3-TF 19.5 2 15 100 ZK8-TF 19 1.8 16 100 ZK9-TF 20 1.5 12 100 ZK10-TF 16.5 1.5 155 100 Production of PLGA-based blended nanofiber formulations via electrospinning method. To provide controlled release with a more hydrophobic structure as an alternative to existing formulations. Nanofiber formulations have been developed using PLGA polymers. 17 Table 17. Production parameters of PLGA-based formulations loaded with TDF and FTC. Code Voltage (kV) Flow Rate (mL / hr) Distance (mm) Collector Rotation Speed (rpm) M1-TF 21 0.5 90 100 M2-TF 19 1.1 100 100 M3-TF 20.5 0.7 95 100 Production of Layered Nanofiber Formulations by Electrospinning Method In layered nanofibers developed as an alternative to formulations produced as a mixture with PLGA, 5 The PLGA formulation forming the middle layer is S1-TF (In vivo Group D), S2-TF, S3-TF, S4-TF In the formulations, 10% PLGA is used, while in the E-TF formulation, it is prepared with 9% PLGA. Layers containing PLGA have a voltage range of 19-20 kV and a fabrication distance of 100-110 mm. It is produced at a flow rate of 1.5 mL / h. During production, the collector's rotation speed is kept constant at 100 rpm. It has been captured. Fiber production has been successfully carried out. PLGA concentration and solvent system 10 The study was conducted in accordance with the guidelines in the literature. The amount of PVA solution used for the PVA layer is kept constant. The voltage values ​​have been changed to 18-19 kV and the flow rate to 1.2-1.5 mL / h in the production of PVA nanofibers. Production was carried out in the 150 mm-160 mm range using the given values. Structural characterization studies in nanofiber formulations The structural design is achieved by using the electrospinning process in the production of nanofibers. Thermal and spectroscopic methods were used to analyze the changes and properties of the nanofibers produced. Characterization studies were carried out using various methods. These studies focused on drug administration. The structural properties of nanofibers affect the active ingredients or the 20 components that occur in the formulations. This helps us understand how it will affect us depending on the changes, in in vitro or in vivo settings. It will help us learn about their effects. Nanofibers for structural studies. DSC, XRD, and FTIR analyses were performed on the formulations. DSC studies examine the glass transition temperatures of polymers and active substances, and whether they are crystalline or amorphous. It will provide information about their structures. FTIR analyses reveal structural and characteristic bonds in substances. 25 It will provide information about it. XRD studies similarly provide information about active substances and polymers. The electrospinning process will provide information about the crystal properties of their structures. Characterization studies of nanofiber formulations. To determine the characteristics of the prepared vaginal nanofibers, TDF, FTC, and polymers were analyzed using DSC 30. The thermograms obtained from the analyses were examined. The structural design is achieved by using the electrospinning process in the production of nanofibers. Thermal and spectroscopic methods were used to analyze the changes and properties of the nanofibers produced. Characterization studies were carried out using various methods. Nanofibers were used for structural studies. DSC, XRD, and FTIR analyses were applied to the formulations. 35 Suitability of nanofiber formulations developed by electrospinning for use in the vagina 18 in-vitro studies to evaluate and determine the amount of active ingredient. Tensile testing and mucoadhesion testing were performed for the mechanical characterization of nanofibers. Experimental characterization studies, such as contact angle tests, have been conducted. In-vitro studies, in It was carried out in a way that simulates in vivo applications. 5 Electron microscopy was used to determine the morphological characteristics of nanofiber formulations. imaging, fiber diameter and distribution, porosity, active substance loading efficiency, mechanical properties Determination of elongation at break and tensile strength for flexibility and resistance, determination of contact angle, BET in vitro release was performed using surface area analysis, Franz diffusion cell and USP basket test. Studies, as ex vivo studies, examined permeability, retention, mucoadhesion, and stability. The studies have been implemented. 10 Active ingredients were added to the Zein-containing nanofiber formulations that were found to be suitable, and the following were created: These properties were found. According to these data, zein-based nanofibers containing TDF and FTC The viscosity specification of the polymer solutions in their formulations is 300-600 cP.s, and their conductivity is... The surface tension is estimated to be 550-1300 µS / cm and 25-30 mN.m−1. Table 18. Polymer solutions of zein-based nanofiber formulations containing TDF and FTC. characterization results Formulation Code Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) Z2-TF 362±10.52 1199±4 27.35±0.07 ZN3-TF 366±11.07 741.33±2.27 27.57±0.29 ZK3-TF 546±2.30 766.47±2.55 28.80±0.11 ZK8-TF 442±17.57 616±8.32 28.18±0.11 ZK9-TF 543.33±19.50 887.37±11.50 28.73±0.06 Solution properties in PVA preformulation studies. Nanofiber formulations created with different types of PVA for pre-formulation studies The results are given in the table. Table 19. Polymer solutions developed from PVA preformulation studies. Characterization results 25 Formulation Code Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) P1 41.42±2.87 174.73±4.97 43.74±0.20 P2 349.67±2.89 152.27±0.51 43.00±0.03 P3 542±0 129.47±2.26 42.11±0.08 19 P4 183.89±4.97 18.46±0.11 46.01±0.10 P5 699.11±2.87 32.31±0.30 43.01±0.02 P6 1740.16±93.91 36.49±0.23 44.78±0.07 P7 805.14±24.85 67.51±0.14 44.92±0.04 P8 1960±5.739 97.82±0.35 42.72±0.13 P9 2909±80.29 95.61±0.74 45.67±0.03 Solution properties of PVA nanofiber formulations developed through experimental design The formulations developed with PVA, listed side-by-side, are the same solution and differ in design and production. The process parameters are changing. Table 20. Polymer solutions developed for design formulations made with PVA. characterization results Formulation Codes Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) RUN 1 RUN 3 395±26 149.8±1.2 30.98±0.15 RUN 2 RUN 7 219±0 158.4±0.4 42.34±0.10 RUN 4 RUN 6 2497±0 226.2±0.7 41.97±0.07 RUN 5 RUN 8 2672±0 212.2±0.8 32.97±0.15 Solution properties of PVA-based mucoadhesive nanofiber formulations. To develop mucoadhesive nanofiber formulations, 10 different polymers were combined with PVA. It has been used. Table 21. Polymer solutions of PVA-based mucoadhesive nanofiber formulations. characterization Formulation Code Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) F1 531±0 194.5±2.456 5.61±0.380 F2 511.33±2.89 99.26±1.02 39.89±0.65 F3 1427.67±2.89 63.82±0.615 41.36±0.63 F4 4388.67±4.51 238.07±3.35 27.47±0.69 F5 530.13±17.45 22.38±0.46 22.38±0.46 F6 1497.67±12.58 1013.0±4.58 35.4±0.80 F7 530.13±17.45 22.38±0.46 22.38±0.46 Table 22. Optimal selection of PVA-based mucoadhesive nanofiber formulations. Characterization of TDF and FTC loaded polymer solutions produced by formulations Formulation Code Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) F1-TF 536.33±1.1547 196.5±1.789 35.91±0.18 F2-TF 1347.67±11.02 184.43±0.21 34.86±0.27 F3-TF 4631±19.5 305±1 39±0.15 F4-TF 1989±0 189.43±0.50 33.66±0.24 Solution properties of zein-containing nanofiber formulations 5 Table 23. Characterization results of polymer solutions prepared with zein. Formulation Code Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) Formulations containing zein Z1 44±0 1238.33±1.52 22.66±0.05 Z2 309.33±1.15 1312.33±1.52 22.13±0.32 Formulations containing Zein-PEO WSR205 ZW0 237±5.19 46.64±0.50 45.20±0.72 ZW1 320.33±11.15 318.77±4.90 47.48±0.90 ZW2 56.66±1.15 638.50±0.45 23.80±0.03 ZW3 95±0 887.10±2.28 23.70±0.10 ZW4 175.66±1.15 1208±2 23.02±0.06 Formulations containing Zein-PEO N80 ZN0 326.33±14.5 23.99±0.29 31.30±0.24 ZN1 354.33±16.65 146.6±6.36 29.63±0.15 ZN2 329±0 501.83±1.15 23.68±0.04 ZN3 384.33±1.15 866.70±1.35 23.98±0.03 ZN4 431.33±1.15 1208.33±0.57 23.47±0.02 ZN5 572.33±1.15 1315.66±2.08 23.23±0.04 Formulations containing Zein-PVP ZK0 338.67±28.91 42.76±2.96 29.25±0.11 ZK1 247.33±41 269.2±11.79 28.79±0.16 ZK2 485.66±1.15 609.77±0.57 27.23±5.93 ZK3 536.33±4.16 815.93±3.05 23.42±0.09 ZK4 952.66±3.05 1026.66±1.52 23.23±0.10 ZK5 953.33±6.42 1164±4.58 23.6±0.62 ZK6 402.33±35.23 23.88±1.33 27.14±0.67 ZK7 423±24 99.73±2.29 29.72±0.22 21 ZK8 470±0 465.10±4.11 23.05±0.18 ZK9 525.67±1.15 751.73±10.96 22.99±0.47 The active ingredients were added to the suitable solutions and 'TF' was added to their formulation codes. They are described as formulations containing both substances. Solution properties of PLGA-based mixed nanofiber formulations The active ingredients were added to the suitable solutions and 'TF' was added to their formulation codes. They are described as formulations containing both substances. Active ingredients were added to the suitable PLGA-containing nanofiber formulations, and the following were prepared: These properties were found. According to these data, PLGA-based nanofibers containing TDF and FTC... The viscosity specification of the polymer solutions in their formulations is 300-650 cP.s, and their conductivity is 15- A surface tension of 500 µS / cm and 25-38 mN.m−1 is predicted. Table 24. Polymer of PLGA-based blend formulations containing TDF and FTC. Characterization results of the solutions Code Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN.m−1) M1-TF 346.67±3.06 18.31±0.12 28.39±1.10 M2-TF 612.97±4.59 453.76±0.77 35.89±3.48 M3-TF 397.67±7.57 51.92±0.78 32.04±0.14 The solution properties of layered fiber formulations produced with TDF and FTC-loaded PLGA are as follows: The values ​​were measured. According to these data, the middle layer containing TDF and FTC with 10% PLGA is 15 Viscosity specification 900-960 cP.s, conductivity 32-40 µS / cm, surface tension 32-40 mN.m−1 Specifically, the viscosity specification of the inner or outer layer containing 10% PVA is 500-600 cP.s. The conductivity is predicted to be 175-215 µS / cm, and the surface tension 32-40 mN.m−1. Solution properties of layered nanofiber formulations 20 Table 25. Solution of layered fiber formulations produced with TDF and FTC loaded PLGA. characterization Layered Formulation Composition Viscosity (cP.s) Conductivity (µS / cm) Surface Tension (mN / m) Middle layer including TDF and FTC. PLGA (10%) 927,667±30,005 35,238±0,342 35,717±0,811 Inner and Outer Layer PVA (10%) 531±0 194.5±2.456 35.61±0.380 22 In Vitro Characterization Studies of Nanofiber Formulations The desired properties and structural requirements of the developed vaginal nanofiber formulations. In vitro characterization studies were carried out to evaluate the findings. Morphological characteristics of nanofiber formulations To observe the structures and arrangements of nanofibers, nanofiber formulations were analyzed using SEM 5. Images have been taken. Table 26. Fiber diameters and porosity of PVA nanofibers developed by experimental design. values Formulation Code Nanofiber Diameter (Mean±SD) Porosity (%) RUN 1 310.018±71.326 88.01 RUN 2 195.712±41.159 73.92 RUN 3 333.469±73.874 61.57 RUN 4 529.335±119.254 65.45 RUN 5 1721.085±113.579 57.18 RUN 6 390.637±56.537 68.76 RUN 7 219.574±29.017 75.98 RUN 8 825,067±115,789 78,61 PVA-based mucoadhesive nanofiber formulations Table 27. Fiber diameters and 10 of nanofiber formulations containing PVA-based mucoadhesive polymer. porosity values Formulation Code Fiber Diameter (nm) Porosity Measurements (%) F1 141.461±44.064 83.10 F2 174.16±71.26 82.59 F3 173.06±75.03 88.68 F4 665.46±144.67 75.28 F5 247.24±84.04 91.12 F6 143.58±75.90 87.99 23 Table 28. Nanofiber containing PVA-based combined mucoadhesive polymer with TDF and FTC. fiber diameters and porosity values ​​of their formulations Formulation Code Fiber Diameter (nm) Porosity Measurements (%) F1-TF 339.795±128.164 83.23 F2-TF 432.293±201.126 58.99 F3-TF 828.685±44.081 48.24 F4-TF 693.402±120.695 49.33 Zein-based nanofiber formulations Table 29. Fiber diameters and porosity values ​​of zein-based nanofiber formulations. Formulation Code Fiber Diameter (nm) Porosity Measurements (%) Z1 127.896±46.212 62.16 Z2 239.684±115.792 55.78 ZW2 477.617±110.466 69.62 ZW3 1658.242±695.677 60.54 ZW4 2553.760±1158.028 42.32 ZN2 297.843±111.473 51.26 ZN3 527.214±167.178 66.03 ZN4 1098.421±468.775 60.95 ZN5 2538.829±1356.231 51.45 ZK1 341.141±124.654 71.78 ZK3 581.682±268.433 58.52 ZK4 1836.530±933.900 56.06 ZK5 2285.209±1489.735 53.98 ZK7 477.611±176.885 64.18 ZK9 977.988±500.015 59.58 Table 30. Fiber diameters of zein-based nanofiber formulations containing TDF and FTC. porosity values Formulation Code Fiber Diameter (nm) Porosity Measurements (%) Z2-TF 622.186±224.595 49.93 ZN3-TF 930.562±288.658 50.35 ZK3-TF 790.959±289.828 59.53 ZK8-TF 898.048±300.838 60.03 ZK9-TF 1312.144±402.374 43.77 24 PLGA-based blended nanofiber formulations Table 31. Fiber diameters and porosity values ​​of PLGA-based nanofiber formulations. Formulation Code Fiber Diameter (nm) Porosity Measurements (%) M1-TF 179.327±75.213 52.98 M2-TF 738.995±138.147 45.88 M3-TF 633.922±434.378 42.53 Layered nanofiber formulations Table 32. Fiber diameter and porosity values ​​of layered PLGA nanofiber formulation. Formulation Code Fiber Diameter (nm) Porosity Measurements (%) S1-TF 286.102±52.617 47.26 Determination of active ingredient loading efficiency in nanofiber formulations. Table 33. TDF and FTC upload activity. Formulation Code TDF FTC F1-TF 91.32±9.101 90.99±9.460 F2-TF 71.05±1.915 71.90±1.772 F4-TF 85.41±11.97 85.14±12.45 ZK7-TF 74.96±14.21 104.88±21.74 ZK10-TF 82.02±13.52 101.30±23.71 Z2-TF 97.11±3.45 84.61±12.32 M2-TF 102.43±24.6 73.61±10.93 S1-TF 75.90±9.45 87.05±34.30 Investigation of the mechanical properties of nanofiber formulations. PVA Preformulation Nanofiber Formulations Table 34. Characterization of nanofiber formulations developed with different PVA types. results Formulation Code Tensile Strength (MPa) Elongation at Break (%) P1 ND* ND* P2 4.106±1.104 48.546±30.590 P3 3.488±0.560 65.746±15.013 P4 1.910±0.416 31.043±7.454 P5 1.383±0.065 125.423±36.801 P6 5,438±1,062 170,677±73,885 P7 2.747±0.158 69.030±13.643 P8 3.450±0.248 93.190±23.450 P9 6,438±1,467 100,267±36,447 *Unmeasurable 5 PVA nanofiber formulations developed through experimental design. Table 35. Characterization results of formulations determined by experimental design. Formulation Code Tensile Strength (MPa) Elongation at Break (%) RUN 1 1.412±0.065 96.207±21.496 RUN 2 1.761±0.023 23.953±2.120 RUN 3 1.657±0.133 73.124±6.156 RUN 4 1.55±0.035 26.897±7.988 RUN 5 3.363±0.177 95.128±19.326 RUN 6 3.915±0.140 94.77±2.744 RUN 7 3.396±0.404 121.727±21.956 RUN 8 3.469±0.379 124.773±9.779 26 Determining the processing parameters of nanofibers using experimental design. findings Using Design Expert software, 23 (2 levels, 3 factors) factorial designs were created and 8 The formulation was prepared. The results obtained were statistically evaluated and independently analyzed. The effects of variables on the mechanical properties of nanofiber formulations were investigated. 5 studies were conducted. The experimental design result and the analysis of all parameters by the program software were suitable for the model. It has not shown any significance. Table 36. Effect of processing parameters on tensile strength of PVA nanofiber formulations. examining its effect using analysis of variance PB Source Sum of Squares Mean Square F-value Significance(p) Model 5843.72 5843.72 7.65 0.0326 A-Concentration 5843.72 5843.72 7.65 With PVA and a 23 factorial design, the tensile strength was found to be 0.991000+7.20723*A'. 10 The effect of the solvent system and the solvent system on the mechanical properties of nanofibers was statistically determined. It has been evaluated. Table 37. Elongation at break of PVA nanofiber formulations under processing parameters. Examining its effect on 15 using analysis of variance. PB Source Sum of Squares Mean Square F-value Significance (p) Model 5843.72 5843.72 7.65 0.0326 A-Concentration 5843.72 5843.72 7.65 PVA-based mucoadhesive nanofiber formulations Table 38. Mechanical characterization of mucoadhesive nanofiber formulations. Formulation Code Tensile Strength (MPa) Elongation at Break (%) F1 5.839±0.462 100.513±15.836 F2 4.514±0.196 113.237±4.293 F3 3.698±0.535 104.207±2.113 F4 6.428±0.104 66.887±0.857 F5 7.122±0.035 41.533±3.285 27 Table 39. Mechanistic analysis of mucoadhesive nanofiber formulations containing TDF and FTC. characterization Formulation Code Tensile Strength (MPa) Elongation at Break (%) F1-TF 5.419±0.500 101.007±5.654 F2-TF 3.299±0.123 16.043±0.652 F4-TF 3.168±0.320 41.050±14.141 Mechanical characterization of Zein-based Nanofiber Formulations Table 40. Characterization of zein-based nanofiber formulations. Formulation Code Tensile Strength (MPa) Elongation at Break (%) Z1 *** Z2 0.501±0.132 0.780±0.439 ZW0 *** ZW1 *** ZW2 *** ZW3 0.691±0.088 2.273±1.239 ZW4 0.644±0.228 0.623±0.031 ZN0 *** ZN1 0.989±0.055 43.660±2.983 ZN2 0.650±0.190 4.877±0.206 ZN3 0.8085±0.033 5.583±0.437 ZN4 0.634±0.190 0.210±0.026 ZN5 0.503±0.064 0±0 ZK0 2.866±0.145 17.067±1.508 ZK1 1.471±0.120 3.243±0.585 ZK2 0.302±0.029 0.900±0.329 ZK3 0.607±0.053 2.943±1.639 ZK4 0.396±0.154 0.140±0.242 ZK5 0.682±0.029 0.010±0 ZK6 4.538±0.307 25.823±4.070 ZK7 3.160±0.217 4.950±0.279 ZK8 1.847±0.084 6.417±0.666 ZK9 1.345±0.112 0.357±0.161 *: Measurement could not be taken. 5 28 Table 41. Characterization of zein-based nanofiber formulations containing TDF and FTC. Formulation Code Tensile Strength (MPa) Elongation at Break (%) Z2-TF 0.452±0.11 1.423±2.457 ZN3-TF 0.172±0.041 1.603±0.140 ZK3-TF 0.439±0.059 2.010±0.555 ZK7-TF 1.510±0.501 2.617±0.977 ZK8-TF 1.525±0.090 4.223±2.002 ZK9-TF 1.143±0.220 1.757±0.796 Mixed nanofiber formulations developed with PLGA. Table 42. Mechanical properties of PLGA-based layered nanofiber formulations containing TDF and FTC. characterization 5 Formulation Code Stress (MPa) Elongation at Break (%) M1-TF 2.644±0.233 78.82±16.81 M2-TF 3.741±0.343 80.13±10.14 M3-TF *** Layered nanofiber formulations developed with PLGA Table 43. Mechanical properties of PLGA-based layered nanofiber formulations containing TDF and FTC. characterization Formulation Code Stress (MPa) Elongation at Break (%) S1-TF 2.374±0.32 26.877±5.249 S2-TF 1.262±0.056 16.363±0.545 S3-TF 1.954±0.219 10.513±3.197 S4-TF 1.330 ± 0.038 19.123 ± 2.055 29 Measurement of contact angles of nanofiber formulations. PVA preformulation nanofiber formulations Table 44. Contact angle measurements of PVA preformulation nanofiber formulations. Formulation Code | Contact Angle (°) P1 ND* P2 17.29±2.69 P3 0±0 P4 0±0 P5 11.07±5.52 P6 19.62±5.21 P7 15.73±1.27 P8 24.78±0.71 P9 38.98±10.62 *Unable to measure Design-enhanced nanofiber formulations 5 All contact angle measurements of the PVA nanofiber formulations developed through this design were found to be 0. Depending on the PVA polymer used, the nanofibers produced are hydrophilic. PVA-based mucoadhesive nanofiber formulations In mucoadhesive formulations developed with PVA, the polymers used have hydrophilic properties. Therefore, the contact angles were found to be 0°. Zein-based nanofiber formulations Table 45. Contact angle characterization of zein-based nanofiber formulations. Formulation Code | Contact Angle Z1 29.15±10.97 Z2 41.39±3.27 ZW0 * ZW1 0 ZW2 * ZW3 48.40±1.90 ZW4 63.20±2.53 ZN0 0 ZN1 0 ZN2 63.67±4.73 ZN3 73.19±1.71 ZN4 79.67±4.02 ZN5 51.94±2.24 ZK0 0 ZK1 0 ZK2 49.85±1.09 ZK3 76.76±3.13 ZK4 100.69±3.06 ZK5 20.99±1.94 ZK6 0 ZK7 0 ZK8 0 ZK9 74.41±5.17 Table 46. Contact angle measurements of zein-based nanofiber formulations containing TDF and FTC. Formulation Code | Contact Angle (°) Z2-TF 25±2.23 ZN3-TF 0 ZK3-TF 0 ZK8-TF 0 ZK9-TF 0 31 Mixture nanofiber formulations prepared with PLGA Table 47. Contact angle measurements of mixed nanofiber formulations prepared with PLGA. Formulation Code | Contact Angle (°) M1 30±1.12 M2 0 M3 0 Layered nanofiber formulations developed with PLGA PLGA-based layered nanofibers, on the other hand, have a hydraulically charged PVA outer layer, which allows for contact angle measurements. It was obtained as 0. 5 Surface area analysis of nanofibers using BET Table 48. Results of multipoint BET analysis of nanofiber formulations. Formulation Code Specific surface area (m² / g) F4-TF 30,099 M2-TF 2,143 S1-TF 6,745 Table 49. Release results of formulations tested with Franz diffusion cells at 8 hours. and the cumulative percentage amounts at 24 hours are 10 Formulation Code The cumulative amount released in the first 8 hours is %, the cumulative amount released in 24 hours is % TDF FTC TDF FTC F1-TF 93.404±17.156 92.578±13.541 101.525±4.522 99.191±3.386 F2-TF 92.199±11.908 99.745±13.893 96.292±15.077 101.087±11.094 F4-TF 90.078±18.013 95.365±16.822 94.602±18.663 98.845±16.773 Z2-TF 25.872±3.985 57.329±6.205 32.397±5.748 63.732±7.582 ZK7-TF 66.565±5.181 77.944±11.148 67.058±5.389 78.282±11.150 ZK8-TF 88.101±6.455 88.021±10.42 89.121±14.256 89.116±10.679 ZK9-TF 95.816±10.947 99.937±10.413 99.937±10.413 102.422±10.324 ZK10-TF 93.812±6.167 94.449±.578 98.118±5.962 102.210±9.256 M1-TF 74.578±15.947 85.501±12.241 78.669±16.792 95.267±14.433 M2-TF 83.878±6.511 87.389±17.316 85.662±6.365 89.165±17.251 S1-TF 67.488±4.988 93.546±6.86 79.849±9.745 99.575±6.598 S2-TF 45.971±4.789 60.963±5.667 57.443±4.613 65.465±4.985 S3-TF 45.971±9.960 41.259±10.651 63.112±10.679 52.006±10.604 S4-TF 34.838±2.536 32.058±2.265 44.507±3.121 36.172±2.466 32 Table 50. Stability results of the F4-TF nanofiber formulation. Appearance Contact Angle (°) Quantity Determination (µg / cm2) TDF FTC 4°C / ambient humidity Initial White 0 99.1±2.5 57.4±2.3 Month 1 White 0 94.7±4.8 56.53±5.2 25°C / 60% relative humidity Initial White 0 99.1±2.5 57.4±2.3 Month 1 White 0 101.6±1.2 54.53±2.8 40°C / 75% relative humidity Initial White 0 99.1±2.5 57.4±2.3 Month 1 White 0 101.2±0.9 60.9±1.4 Table 51. Stability results of the M2-TF nanofiber formulation. Appearance Contact Angle (°) Quantity Determination (µg / cm2) TDF FTC 4°C / ambient humidity Initial White 35.2±2.5 83.2±1.41 69.8±1.3 Month 1 White 32.5±1.3 86.7±8.1 68.7±1.9 25°C / 60% relative humidity Initial White 35.2±2.5 83.2±1.41 69.8±1.3 Month 1 White 34.5±1.3 84.4±2.6 68.5±1.1 40°C / 75% relative humidity Initial White 35.2±2.5 83.2±1.41 69.8±1.3 Month 1 White 36.3±1.3 85.2±0.5 67.5±5.4 Table 52. Stability results of the S1-TF nanofiber formulation. View Contact Angle (°) Quantification TDF FTC 4°C / ambient humidity Initial White 0 106.4±1.8 86.4±8.1 Month 1 White 0 107.5±2.6 85.7±6.4 25°C / 60% relative humidity moisture Initial White 0 106.4±1.8 86.4±8.1 Month 1 White 0 105.7±4.9 84.3±4.2 40°C / 75% relative humidity moisture Initial White 0 106.4±1.8 86.4±8.1 Month 1 White 0 103.9±6.5 87.6±2.4

Claims

33 REQUESTS 1. It is a layered nanofiber formulation produced by the electrospinning method, • Inner layer containing PVA, 5 • Release regulator with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) a middle layer containing zein or PLGA as a polymer, • It consists of three layers, with an outer layer containing PVA.

2. Nanofiber formulation according to Claim 1, with PVA molecular weight approximately 49000, 80000 or 10 It is 100,000 g / mol.

3. Nanofiber formulation according to claim 1 or 2, with PVA molecular weight approximately 49000 It is in g / mol.

4. Nanofiber formulation according to claim 3, PVA to distilled water:ethanol in a 1:1 volume ratio. It is prepared with a 10% concentration.

4. A nanofiber formulation according to any of claims 1-3, with a middle layer polymer. It contains zein. 20 5. A nanofiber formulation according to any of claims 1-3, with a polymer as the middle layer. Includes PLGA.

6. This is a nanofiber formulation according to Claim 1, and 25 by volume is required for the preparation of PLGA nanofibers. A 9:1 ratio of Acetone:DMF solvent is used.

7. It is a nanofiber formulation according to Claim 1, and is used internally and / or externally to enhance its mucoadhesive properties. The outer layer contains a polymer selected from PVP, PEO, pullulan, gluten, and chitosan.

8. It is a nanofiber formulation according to claim 7, and the inner and / or outer layer has mucoadhesive properties. Includes PVP to enhance the experience.

8. It is a layered nanofiber formulation produced by the electrospinning method, 35 • Inner layer containing PVA and PVP, • Release regulator with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) a middle layer containing zein or PLGA as a polymer, • It consists of three layers, including an outer layer containing PVA and PVP. 40 9. It is a nanofiber formulation according to claim 8, containing zein as the middle layer polymer.

10. It is a nanofiber formulation according to claim 8, containing PLGA as the middle layer polymer.

11. Nanofiber formulation according to claim 1 or 8, containing 90 mg Tenofovir Disoproxil Fumarate and 45 It contains 60mg of emtricitabine.

12. For use in local prophylaxis to prevent vaginal transmission of HIV / AIDS. Nanofiber formulation according to claim 1 or 8.